Sionna Therapeutics, Common Stock Alpha and Beta Analysis
| SION Stock | 43.70 0.33 0.75% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Sionna Therapeutics, Common. It also helps investors analyze the systematic and unsystematic risks associated with investing in Sionna Therapeutics, over a specified time horizon. Remember, high Sionna Therapeutics,'s alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Sionna Therapeutics,'s market risk premium analysis include:
Beta 1.14 | Alpha 0.75 | Risk 5.18 | Sharpe Ratio 0.14 | Expected Return 0.73 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Sionna Therapeutics, Backtesting, Sionna Therapeutics, Valuation, Sionna Therapeutics, Correlation, Sionna Therapeutics, Hype Analysis, Sionna Therapeutics, Volatility, Sionna Therapeutics, History and analyze Sionna Therapeutics, Performance. Sionna Therapeutics, Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Sionna Therapeutics, market risk premium is the additional return an investor will receive from holding Sionna Therapeutics, long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Sionna Therapeutics,. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Sionna Therapeutics,'s performance over market.| α | 0.75 | β | 1.14 |
Sionna Therapeutics, expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Sionna Therapeutics,'s Buy-and-hold return. Our buy-and-hold chart shows how Sionna Therapeutics, performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Sionna Therapeutics, Market Price Analysis
Market price analysis indicators help investors to evaluate how Sionna Therapeutics, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Sionna Therapeutics, shares will generate the highest return on investment. By understating and applying Sionna Therapeutics, stock market price indicators, traders can identify Sionna Therapeutics, position entry and exit signals to maximize returns.
Sionna Therapeutics, Return and Market Media
The median price of Sionna Therapeutics, for the period between Sun, Sep 28, 2025 and Sat, Dec 27, 2025 is 38.41 with a coefficient of variation of 14.77. The daily time series for the period is distributed with a sample standard deviation of 5.47, arithmetic mean of 37.03, and mean deviation of 4.69. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 2047 shares by Booth Bruce of Sionna Therapeutics, at 29.95 subject to Rule 16b-3 | 10/06/2025 |
2 | Disposition of 857 shares by Booth Bruce of Sionna Therapeutics, at 31.03 subject to Rule 16b-3 | 10/13/2025 |
3 | Disposition of 105 shares by Booth Bruce of Sionna Therapeutics, at 29.95 subject to Rule 16b-3 | 10/14/2025 |
4 | Disposition of 200 shares by Cloonan Michael of Sionna Therapeutics, at 6.11 subject to Rule 16b-3 | 10/16/2025 |
5 | Disposition of 5412 shares by Booth Bruce of Sionna Therapeutics, at 32.33 subject to Rule 16b-3 | 10/20/2025 |
6 | Disposition of 10476 shares by Ra Capital Management, L.p. of Sionna Therapeutics, at .58 subject to Rule 16b-3 | 10/28/2025 |
7 | Disposition of 19948 shares by Booth Bruce of Sionna Therapeutics, at 33.87 subject to Rule 16b-3 | 11/07/2025 |
8 | Disposition of 6303 shares by Booth Bruce of Sionna Therapeutics, at 31.12 subject to Rule 16b-3 | 11/13/2025 |
9 | Disposition of 14775 shares by Cloonan Michael of Sionna Therapeutics, at 6.11 subject to Rule 16b-3 | 11/14/2025 |
10 | Disposition of 2092 shares by Ra Capital Management, L.p. of Sionna Therapeutics, at .57 subject to Rule 16b-3 | 11/18/2025 |
11 | Ra Capital Management, L.P. Sells 6,922 Shares of Sionna Therapeutics Stock | 11/20/2025 |
12 | Ra Capital Management, L.P. Sells 47,442 Shares of Sionna Therapeutics Stock | 11/21/2025 |
13 | Sionna Therapeutics to Participate in Upcoming December Investor Conferences | 11/24/2025 |
14 | Disposition of 11890 shares by Thompson Peter A. of Sionna Therapeutics, at 44.6 subject to Rule 16b-3 | 11/25/2025 |
15 | Sionna Therapeutics Earns Underperform Rating from Royal Bank Of Canada | 12/01/2025 |
16 | Disposition of 30049 shares by Cloonan Michael of Sionna Therapeutics, at 6.11 subject to Rule 16b-3 | 12/02/2025 |
17 | Disposition of 10250 shares by Jennifer Fitzpatrick of Sionna Therapeutics, at 40.52 subject to Rule 16b-3 | 12/05/2025 |
18 | Sionna Therapeutics chief legal officer sells 415,330 in stock - Investing.com | 12/09/2025 |
19 | Disposition of 801 shares by Ra Capital Management, L.p. of Sionna Therapeutics, at .89 subject to Rule 16b-3 | 12/12/2025 |
20 | Disposition of 900 shares by Thompson Peter A. of Sionna Therapeutics, at 44.5 subject to Rule 16b-3 | 12/17/2025 |
21 | Disposition of 100 shares by Thompson Peter A. of Sionna Therapeutics, at 44.49 subject to Rule 16b-3 | 12/18/2025 |
22 | Disposition of 875 shares by Thompson Peter A. of Sionna Therapeutics, at 44.49 subject to Rule 16b-3 | 12/19/2025 |
23 | Is Simonds Group Limiteds Stock Price Struggling As A Result Of Its Mixed Financials | 12/24/2025 |
About Sionna Therapeutics, Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Sionna or other stocks. Alpha measures the amount that position in Sionna Therapeutics, has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2023 | 2024 | 2025 (projected) | ROE | 0.58 | 0.41 | 0.38 | 0.5 | Income Quality | 0.9 | 0.92 | 0.86 | 0.98 |
Sionna Therapeutics, Investors Sentiment
The influence of Sionna Therapeutics,'s investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Sionna. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Sionna Therapeutics,'s public news can be used to forecast risks associated with an investment in Sionna. The trend in average sentiment can be used to explain how an investor holding Sionna can time the market purely based on public headlines and social activities around Sionna Therapeutics, Common. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Sionna Therapeutics,'s market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Sionna Therapeutics,'s and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Sionna Therapeutics,'s news discussions. The higher the estimated score, the more favorable is the investor's outlook on Sionna Therapeutics,.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sionna Therapeutics, in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sionna Therapeutics,'s short interest history, or implied volatility extrapolated from Sionna Therapeutics, options trading.
Build Portfolio with Sionna Therapeutics,
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Sionna Therapeutics, Backtesting, Sionna Therapeutics, Valuation, Sionna Therapeutics, Correlation, Sionna Therapeutics, Hype Analysis, Sionna Therapeutics, Volatility, Sionna Therapeutics, History and analyze Sionna Therapeutics, Performance. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Sionna Therapeutics, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.